Multiple relapses in high-grade osteosarcoma: When to stop aggressive therapy?-Reference-Cited by-同舟云学术

Multiple relapses in high-grade osteosarcoma: When to stop aggressive therapy?

Published:2014-12-08 Issue:3 Volume:62 Page:529-530
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Tamamyan Gevorg¹,Dominkus Martin²,Lang Susanna³,Diakos Christopher¹,Mittheisz Edda¹,Horcher Ernst⁴,Holter Wolfgang¹⁵,Zoubek Andreas¹,Bielack Stefan⁶,Kager Leo¹⁵

Affiliation:

1. Department of Pediatrics; St. Anna Children's Hospital; Medical University Vienna; Vienna Austria

2. Orthopedic Surgery Hospital Speising; Vienna Austria

3. Department of Clinical Pathology; Medical University Vienna; Vienna Austria

4. Department of Pediatric Surgery; Medical University Vienna; Vienna Austria

5. Children's Cancer Research Institute; Vienna Austria

6. Klinikum Stuttgart-Olgahospital; Pediatrics 5 - Oncology, Hematology, Immunology; Stuttgart Germany

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference20 articles.

1. Childhood and adolescent cancer statistics 2014;Ward;CA Cancer J Clin,2014

2. Osteosarcoma treatment - where do we stand? A state of the art review;Luetke;Cancer Treat Rev,2014

3. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS);Kempf-Bielack;J Clin Oncol,2005

4. Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients;Bielack;J Clin Oncol,2009

5. Osteosarcoma: the COSS experience;Bielack;Cancer Treat Res,2009

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncommon metachronous multiple sites recurrences of metastatic osteosarcoma cured by surgery: a case report;Acta Oncologica;2023-08-14

2. MiR-139 inhibits proliferation, migration and invasion of osteosarcoma cell line MG63 via down-regulating integrin subunit alpha V(ITGAV);Tissue and Cell;2022-04

3. A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma;European Journal of Cancer;2020-01

4. An update on emerging drugs in osteosarcoma: towards tailored therapies?;Expert Opinion on Emerging Drugs;2019-07-03

5. Cytotoxic Tolerance of Healthy and Cancerous Bone Cells to Anti-microbial Phenolic Compounds Depend on Culture Conditions;Applied Biochemistry and Biotechnology;2018-12-10